Martin K Bakht

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1822356/publications.pdf

Version: 2024-02-01

759233 713466 23 476 12 21 h-index citations g-index papers 28 28 28 612 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119 , .	7.1	13
2	CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Research, 2022, 82, 3088-3101.	0.9	2
3	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. European Urology, 2021, 79, 722-733.	1.9	17
4	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature Communications, 2021, 12, 3372.	12.8	45
5	Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation. Carcinogenesis, 2020, 41, 850-862.	2.8	3
6	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for ¹⁸ F-FDG Imaging of PSMA-Suppressed Tumors. Journal of Nuclear Medicine, 2020, 61, 904-910.	5.0	52
7	Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-Related Cancer, 2019, 26, 131-146.	3.1	98
8	Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. Nuclear Medicine and Molecular Imaging, 2017, 51, 202-211.	1.0	45
9	Calcium Phosphate Nanoparticles Cytocompatibility Versus Cytotoxicity: A Serendipitous Paradox. Current Pharmaceutical Design, 2017, 23, 2930-2951.	1.9	12
10	The Potential Roles of Radionanomedicine and Radioexosomics in Prostate Cancer Research and Treatment. Current Pharmaceutical Design, 2017, 23, 2976-2990.	1.9	3
11	Feasibility study of FLUKA Monte CarloÂsimulation for a beta-emitting brachytherapy source: dosimetric parameters of 142Pr glass seed. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 947-953.	1.5	3
12	Impact of various color <scp>LED</scp> flashlights and different lighting source to skin distances on the manual and the computerâ€aided detection of basal cell carcinoma borders. Skin Research and Technology, 2014, 20, 92-96.	1.6	1
13	Monte Carlo simulations and radiation dosimetry measurements of 142Pr capillary tube-based radioactive implant (CTRI): a new structure for brachytherapy sources. Annals of Nuclear Medicine, 2013, 27, 253-260.	2.2	1
14	Radiolabeled nanoceria probes may reduce oxidative damages and risk of cancer: A hypothesis for radioisotope-based imaging procedures. Medical Hypotheses, 2013, 81, 1164-1168.	1.5	6
15	production of the radiohalogen <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msup><mml:mrow></mml:mrow><mml:mn>34</mml:mn></mml:msup></mml:math> Cl <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msup><mml:mrow< td=""><td>2.9</td><td>6</td></mml:mrow<></mml:msup></mml:math>	2.9	6
16	/> <mml:mi>mc/mwww.s.ofg/9/9/8/math/wath/wath/wath/wath/wath/wath/wath/w</mml:mi>	1.1	26
17	Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment. Current Cancer Drug Targets, 2012, 12, 998-1015.	1.6	31
18	Overview of mercury radionuclides and nuclear model calculations of 195Hgm, gand 197Hgm, gto evaluate experimental cross section data. Physical Review C, 2012, 85, .	2.9	12

#	Article	IF	CITATION
19	A novel technique for simultaneous diagnosis and radioprotection by radioactive cerium oxide nanoparticles: study of cyclotron production of 137mCe. Journal of Radioanalytical and Nuclear Chemistry, 2012, 292, 53-59.	1.5	27
20	Production of cationic 198Au3+ and nonionic 198Au0 for radionuclide therapy applications via the natAu(n,\hat{l}^3)198Au reaction. Journal of Radioanalytical and Nuclear Chemistry, 2012, 293, 45-49.	1.5	13
21	Bremsstrahlung parameters of praseodymium-142 in different human tissues: a dosimetric perspective for 142Pr radionuclide therapy. Annals of Nuclear Medicine, 2012, 26, 412-418.	2.2	6
22	Practicality of the cyclotron production of radiolanthanide 142Pr: a potential for therapeutic applications and biodistribution studies. Journal of Radioanalytical and Nuclear Chemistry, 2011, 288, 937-942.	1.5	24
23	Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy. Annals of Nuclear Medicine, 2011, 25, 529-535.	2.2	30